ASN Program - Menveo and Engerix B Vaccine Updates
Texas Health and Human Services Commission sent this bulletin at 07/07/2023 11:00 AM CDT / Este e-mail ha sido enviado por Texas Health and Human Services Commission el 07/07/2023 11:00 AM CDT |
The Centers for Disease Control and Prevention (CDC) released the annual vaccine contract updates for products ordered through the ASN program. The following vaccines will be discontinued in the Vaccine Allocation and Ordering System (VAOS) beginning Friday, July 7, 2023, at 5:00 p.m. CST.
- GlaxoSmithKline - Menveo® Single-Dose Vial (MCV4)
- GlaxoSmithKline - Engerix B® Single-Dose Vial (Hepatitis B)
Providers have the option to order alternative Hepatitis B products, such as the pre-filled syringe presentation of Engerix B® and Recombivax HB® (Merck). Additionally, for MCV4 products, providers can order MenQuadfi™ Single-Dose vials (Sanofi).
There is no action required from providers for outstanding orders already entered in VAOS. Please contact your ASN program Responsible Entity (RE) for any questions.
Thank you for your continued participation in the ASN program.
You have subscribed to get updates about Texas Health and Human Services (HHS). For more information about HHS, please visit our website.
| Stay Connected | ||||||
 |
 |
 |
 |
|
(en español) | |
Subscriber Services
Manage Preferences | Unsubscribe | Help